Choose your language:
Facebook
LinkedIn
Twitter
Providing Capital & Management Solutions for Private & Public Companies and Sophisticated Investors

Dr Mark Rainbird

BlueMount Capital Secures Funding for Velocity Property Group (ASX: VP7)

Velocity Property Group’s (Velocity) corporate advisor BlueMount Capital (QLD) Pty Ltd (BlueMount) has assisted with the origination and investment structuring of the recent transaction by 360 Capital entities.

The transaction comprises multiple components, strategies and capital funding sources to reposition Velocity to become a high growth developer of predominantly owner occupier product in south-east Queensland. The transaction value exceeds $10m.

BlueMount’s Managing Director, Dr Mark Rainbird, states “I am delighted to announce that we have assisted with the structuring of the transaction to support Velocity and it’s growth via this cornerstone investment”.

BlueMount Capital worked closely to devise an investment banking initiative to re-capitlize for future growth while engaging discussions with global and local strategic institutional partners.

About Velocity Property Group

Velocity Property Group was established by Managing Director Brendon Ansell and listed on the Australian Stock Exchange (ASX: VP7) in 2017. Velocity Property Group creates luxury, multi-unit developments in south-east Queensland that are specifically designed for the owner-occupier, empty-nester market and mixed use / commercial developments that enhance local communities.

About BlueMount Capital

BlueMount Capital is an Australia based investment firm and corporate finance group assisting and advising corporate clients on listing on the ASX, M&A, private placements, cross border transactions and the raising of capital from the equity and debt markets. For more information please email brisbane@bluemountcapital.com or phone +61 7 3160 2840.

Dr Mark Rainbird
Managing Director,
BlueMount Capital

BlueMount Capital Appointed as Corporate Advisor by Medcan Group Pty Ltd

BlueMount Capital is pleased to advise that we have been appointed as an exclusive Corporate Advisor to the Medcan Group Pty Ltd.

Founded in Australia in 2016, Medcan is a medicinal cannabis cultivation, production, research and manufacturing company aiming to apply state of the art technologies to produce medicinal cannabis and associated medicinal cannabis products. The Company holds the full suite of licences issued by the Australian Office of Drug Control (ODC) and holds the relevant State and Biosecurity licences to allow the execution of Medcan’s business plan. The Company is planning to expand its current import and distribution business and the commissioning of its manufacturing facility.

Key Highlights:

  • Medcan plans to become a complete ‘seed to sale’ facility;
  • The Company has existing import and distribution operations;
  • Medcan is amongst a handful of Australia companies holding the entire suite of Australian Office of Drug Control (ODC) licences:
    • Cannabis Research Licence;
    • Medicinal Cannabis Cultivation and Production Licence;
    • Manufacture Licence;
    • Import & Export Licences;
  • Medcan also holds the following State and Biosecurity licences:
    • Queensland Poisons Licence;
    • Queensland Wholesaling Licence;
    • DAWR Permit
  • The planned Medcan facility fit out has both DA & BA (Local Council) approval;
  • Medcan’s Cannabis Research and Development centre has been constructed and inspected by the Australian Office of Drug Control (ODC – awaiting final permit approval);
  • The Company holds signed offtake agreements for over 65% of production for an approx. value of up to $25m with further offtake agreements in the pipeline;
  • Medcan has also signed manufacturing agreements with other cultivators who intend to use Medcan to process and manufacture their end products.

Market:

  • The Australian Medicinal Cannabis market is forecast to grow from $52m in 2018 to $1.2B in 2027.
  • The global legal marijuana market is expected to reach US$66.3B by the end of 2025 and is anticipated to grow at 23.9% over the period.

BlueMount Capital will strategically assist Medcan with corporate and capital raising advice. For more information please click here or contact us.

Dr Mark Rainbird
Managing Director
BlueMount Capital

BlueMount Capital Secures Expansion Funding for Elite Military Fitness

I am delighted to announce that we have secured AUD $3.5 million in expansion debt financing for Elite Military Fitness (EMF), a leading Gold Coast based fitness and performance group.

EMF has built a chain of fitness and performance centres focused on providing the affordability of a small 24-hour gym, the personal service of a health club and the amenities and equipment of an elite training facility. EMF’s fitness centres were created to bring a more professional and personalised service to the community without the added expense. The Company’s aim is to offer a complete fitness model to the general population; a facility that caters for everyone’s needs without overcrowding and limited equipment.

The funds will be used to expand the group’s footprint, incorporating new centres, as well as providing equipment finance. The funding includes a range of business facilities such as loans, equipment finance, credit cards and a bank guarantee.

BlueMount Capital worked closely with the new funder and the client to secure the facilities, managing the approach to the market, providing financial modelling to support the transaction and negotiating with the financier, plus assisting with closing the transaction. The facilities provided, include flexible covenants for future growth while providing competitive interest rates on all the products offered. The funding is expected to assist in meeting the groups rapid expansion plans.

EMF co-founder Scott Freeman states “BlueMount Capital has been paramount in EMF realising our dream to delivering affordable and innovative health and fitness solutions to the greater Australian community. Their assistance has helped us create our new Nerang Performance and Recovery Centre and will be assisting us with our venture in our North Lakes venue later in 2019. The future for EMF is only looking brighter.”

About BlueMount Capital

BlueMount Capital is an Australia based investment firm and corporate finance group assisting and advising corporate clients on listing on the ASX, M&A, private placements, cross border transactions and the raising of capital from the equity and debt markets. For more information please email brisbane@bluemountcapital.com or phone +61 7 3160 2840.

BlueMount Capital Appointed as Corporate Advisor by Qponics Limited

BlueMount Capital is pleased to advise that we have been appointed Corporate Advisor by Qponics Limited.

Qponics Limited is a Brisbane based company focused on the sustainable production of EPA Omega-3 oils and other high-value products from Australian strains of algae.

The Company is planning to upgrade the existing pilot algae farm, to purchase a property for its commercial algae farm and submitting the DA and preparing to list on a suitable Australian stock exchange via an IPO in 2019.

The upgraded pilot algae farm in Brisbane and Qponics’ largescale algae farm to be built on the proposed 167.5 ha site at South Ballina will sustainably produce algae, from which omega-3 oil and high-protein biomass as a by-product will be extracted, integrating state-of-the-art technologies to maximise automation and minimise operational costs.

Our assignment will comprise being the corporate advisor, and raising funds now for a pre-IPO raising of $7M immediately followed by an IPO in 2019. For more information please click here or contact us.

Dr Mark Rainbird
Managing Director
BlueMount Capital